乳腺癌核素分子显像的临床研究进展

关晏星

乳腺癌核素分子显像的临床研究进展

关晏星

文章导航 > 国际放射医学核医学杂志 > 2006, 30 > 4: (225-228,231)

引用本文:

Citation:

乳腺癌核素分子显像的临床研究进展

关晏星

330006 南昌, 南昌大学第一附属医院核医学科
中图分类号: R817.4

Clinic applicatim and propgress of the nuclide molecular imaging in breast cancer

GUAN Yan-xing

Department of Nuclear Medicine, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China
CLC number: R817.4

摘要: 乳腺癌分子显像不断快速发展,得益于新的更特异的显像剂和显像仪器的发展。当前,¹⁸F-氟代脱氧葡萄糖(¹⁸F-FDG)仍然是最广泛使用的代谢显像剂,但许多针对细胞靶点的更具特异性的示踪剂在发展,如针对DNA复制反映细胞增殖的3'-脱氧.3'-¹⁸F-氟代胸苷(¹⁸F-FLT)、反映细胞凋亡和雌激素受体状况的^99mTc-annexinV和¹⁸F-16α-氟雌二醇、针对HER-2/neu受体的基因工程抗体片段等。同机PET-CT的临床应用不断扩大,专门用于乳腺显像的PET及术中探测放射性强度、指导外科医生对转移淋巴结和恶性病灶准确采样的便携式正电子探测器也正投入研究和应用中。
- 乳腺肿瘤 /
- 放射性核素显像
Abstract: Molecular imaging of breast cancer continues to rapidly expand due to improvements in both instrumentation and newer, more specific tracers.¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) is still the most widely used tumor imaging agent, but a multitude of new PET tracers are under development, many of which are aimed at targeting cellular processes that are more specific than glucose metabolism. These tracers include thymidine analogs such as ¹⁸F-fluoro-L-thymidine (FLT) that target DNA replication as a measure of cell proliferation, annexin V derivatives that evaluate apoptosis, estrogen receptor(ER)tracers such as 16α-(¹⁸F-fluoroestradiol-17β, FES), and engineered antibody fragments that directly target HER-2/neu receptors. PET-CT inline scanning was applicated more and more widely. Other new scanning devices are also being developed, including small gantry PET scanners designed specifically for breast imaging, and handheld PET probes for direct intraoperative localization of tracer-avid tumor foci.
- Breast neoplasms /
- Radionuclide imaging
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Buck AK,Schirmeister H,Mattfeldt T,et al.Biological characterization of breast cancer by means of PET.Eur J Nucl Med Mol Imaging,2004,31(Suppl 1):S80-S87.
[2]	Wu D,Gambhir SS.Positron emission tomography in diagnosis and management of invasive breast cancer:.Current status and future perspectives.Clin Breast Cancer,2003,4(Suppl 1):S55-S63.
[3]	王玲,张炽敏.乳腺肿瘤的影像学诊断进展.国外医学·放射医学核医学分册,2005,29(2):93-96.
[4]	Kumar A.Fluorodeoxyglucose-PET in the management of breast cancer.Radiol Clin North Am,2004,42(6):1113-1122.
[5]	Andrew Q,Sanjiv S G.FDG-PET and beyond:Molecular breast cancer imaging.J Clin Oncol,2005,23(8):1664-1673.
[6]	Wang Y,Yu J,Liu J,et al.PET-CT in the diagnosis of both primary breast cancer and axillary lymph node metastasis:initial experience.Int J Radiat Oncol Biol Phys,2003,57(Suppl 1):362-363.
[7]	Bellon JR,Livingston RB,Eubank WIB.Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer(LABC).Am J Clin Oncol,2004,27(4):407-410.
[8]	Eubank WB,Mankoff DA,Takasugi J,et al.18fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer.J Clin Oncol,2001,19(12):3516-3523.
[9]	Lin WY,Tsai SC,Cheng KY,et al.Fluroine-18 FDG-PET in detecting local recurrence and distant metastases in breast cancer-Taiwanese experiences.Cancer Invest,2002,20(5-6):725-729.
[10]	Pecking Ap,Mechelany-Corone C,Bertrand-kermorgant F,et al.Detection of occult disease in breast cancer using fluorodeoxyglucose camera-based positron emission tomogaphy.Clin Breast Cancer,2001,2(3):229-234.
[11]	Pelosi E,Messa C,Sironi S,et al.Value of integrated PET/CT for lesion localization in cancer patients:A comparative study.Eur J Nucl Med Mol Imaging,2004,31(6):932-939.
[12]	Uematsu T,Yuen S,Yukisawa S,et al.Comparison of FDG PET and SPECT for detection of bone metastases in breast cancer.Am J Roentgenol,2005,184(4):1266-1273.
[13]	Krak NC,Hoekstra OS,Lammertsma AA.Measuring response to chemotherapy in locally advanced breast cancer:methodological considerations.Eur J Nucl Med Mol Imaging,2004,31(Suppl 1):S103-S111.
[14]	Schelling M,Avril N,Nahrig J,et al.Positron emission tomography using[(18)F] fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer.J Clin Oncol,2000,18(18):1689-1695.
[15]	Mortimer JE,Dehdashti F,Siegel BA,et al.Metabolic flare:indicator of hormone responsiveness in advanced breast cancer.J Clin Oncol,2001,19(11):2797-2803.
[16]	Smyczek-Gargya B,Fersis N,Dittmann H,et al.PET with [18F]fluorothymidine for imaging of primary breast cancer:A pilot study.Eur J Nucl Med Mol Imaging,2004,31(5):720-724.
[17]	Pio BS,Park CK,Silverman DH.PET with fluoro-L-thymididne allows early prediction of breast cancer response to chemotherapy.J Nucl Med,2003,44(1):76-77.
[18]	Takamura Y,Miyoshi Y,Taguchi T,et al.Prediction of chemotherapeutic response by Technetium 99m-MIBI scintigraphy in breast carcinoma patients.Cancer,2001,92(2):232-239.
[19]	Fuster D,Munoz M,Pavia J,et al.Quantified ^99mTc-MIBI scintigraphy for predicting chemotherapy response in breast cancer patients:factors that influence the level of ^99mTc-MIBI uptake.Nucl Med Commun,2002,23(1):31-38.
[20]	Kim R,Osaki A,Hirai T,et al.Utility of technetium-99m methoxyisobutyl isonitrile uptake analysis for prediction of the response to chemotherapy in advanced and relapsed breast cancer.Breast Cancer,2002,9(3):240-247.
[21]	Aloj L,Zannetti A,Caraco C,et al.Bcl-2 overexpression prevents ^99mTc-MIBI uptake in breast cancer cell lines.Eur J Nucl Med Mol Imaging,2004,31(4):521-710.
[22]	Del Vecchio S,Salvatore M.^99mTc-MIBI in the evaluation of breast cancer biology.Eur J Nucl Med Mol Imaging,2004,31(Suppl 1):S88-S96.
[23]	Zhoanglin Liu,Stevenson GD,Barrett HH,et al.Imaging recognition of inhibition of multidrug resistance in human breast cancer xenografts using ^99mTc-labeled sestamibi and tetrofosmin.Nucl Med Biol,2005,32(6):573-583.
[24]	Britz-Cunning ham,SH,James-Adelstein S.Molecular targeting with radionuclides:state of the science.J Nucl Med,2003,44(12):1945-1961.
[25]	Bennink RJ,van Tienhoven G,Rijks LJ,et al.In vivo prediction of response to antiestrogen treatment in estrogen receptor-positive breast cancer.J Nucl Med,2004,45(1):1-7.
[26]	Behr TM,Behe M,Angerstein C,et al.Does pretherapeutic immunoscintigraphy allow for diagnostic predictions with respect to the toxicity and therapeutic efficacy of cold immunotherapy with trastuzumab (Herceptin)?.J Nucl Med,2000,41(1):73.
[27]	吴浩荣,吴锦昌.Baum R. ^99mTc标记抗粘蛋白McAb乳腺癌放射免疫显像的临床研究.中华核医学杂志,2000,20(2):75-77.
[28]	Murakami Y,Takamatsu H,Taki J,et al.¹⁸F-labelled annexin V:a PET tracer for apoptosis imaging.Eur J Nucl Med Mol Imaging,2004,31(4):469-474.

[1]	姚兰琳 , 吴华 , 郭崴 . 乳腺癌核素靶向诊疗一体化的研究进展. 国际放射医学核医学杂志, 2020, 44(11): 728-736. doi: 10.3760/cma.j.cn121381-201909026-00081
[2]	汪秀玲 , 侯先存 , 徐凯 . 核医学显像在乳腺癌诊疗中的作用. 国际放射医学核医学杂志, 2006, 30(4): 222-224.
[3]	马乐 , 张万春 , 李晓敏 . 乳腺癌前哨淋巴结核素显像新进展. 国际放射医学核医学杂志, 2016, 40(2): 145-148, 158. doi: 10.3760/cma.j.issn.1673-4114.2016.02.012
[4]	郭睿 , 晋建华 . ^99mTc-depreotide生长抑素受体显像的临床应用研究. 国际放射医学核医学杂志, 2007, 31(3): 154-157.
[5]	王佳琼 , 王自正 , 姚薇萱 , 王峰 . 乳腺肿瘤生长抑素受体表达与生长抑素受体显像. 国际放射医学核医学杂志, 2006, 30(1): 17-21.
[6]	马海彦 , 谢光友 , 张莎莎 , 郑兴菊 , 刘江勇 , 王荣品 . 乳腺专用γ显像的肿瘤/正常组织比值与乳腺浸润性导管癌病理学的对比研究. 国际放射医学核医学杂志, 2020, 44(7): 422-428. doi: 10.3760/cma.j.cn121381-201906010-00058
[7]	刘超 , 邓智勇 , 刘鹏杰 , 贾莉 . ⁸⁹SrCL₂与唑来膦酸联合治疗乳腺癌转移性骨肿瘤的疗效分析. 国际放射医学核医学杂志, 2014, 38(5): 300-303. doi: 10.3760/cma.j.issn.1673-4114.2014.05.006
[8]	刘晓梅 , 魏玲格 , 张芳 . 以血管生成为分子靶点的放射性核素显像分子探针在肿瘤个体化用药中的应用. 国际放射医学核医学杂志, 2017, 41(5): 363-369. doi: 10.3760/cma.j.issn.1673-4114.2017.05.011
[9]	孟召伟 , 董峰 , 谭建 . 乳腺癌的雌激素受体显像. 国际放射医学核医学杂志, 2007, 31(3): 157-159.
[10]	胡鸿 , 唐刚华 , 聂大红 . 乳腺癌分子显像研究进展. 国际放射医学核医学杂志, 2015, 39(1): 91-95. doi: 10.3760/cma.j.issn.1673-4114.2015.01.019

点击查看大图

计量

文章访问数: 1447
HTML全文浏览量: 98
PDF下载量: 3

乳腺癌核素分子显像的临床研究进展

关晏星

330006 南昌, 南昌大学第一附属医院核医学科

收稿日期: 2006-02-25

关键词:

乳腺肿瘤 /
放射性核素显像

摘要: 乳腺癌分子显像不断快速发展,得益于新的更特异的显像剂和显像仪器的发展。当前,¹⁸F-氟代脱氧葡萄糖(¹⁸F-FDG)仍然是最广泛使用的代谢显像剂,但许多针对细胞靶点的更具特异性的示踪剂在发展,如针对DNA复制反映细胞增殖的3'-脱氧.3'-¹⁸F-氟代胸苷(¹⁸F-FLT)、反映细胞凋亡和雌激素受体状况的^99mTc-annexinV和¹⁸F-16α-氟雌二醇、针对HER-2/neu受体的基因工程抗体片段等。同机PET-CT的临床应用不断扩大,专门用于乳腺显像的PET及术中探测放射性强度、指导外科医生对转移淋巴结和恶性病灶准确采样的便携式正电子探测器也正投入研究和应用中。